Vivet Therapeutics, participated by Ysios Capital and Columbus Venture, closes an exclusive license option with Mirum Pharmaceuticals

Inversión, Venture Capital

13/04/2021 Press release MIRUM PHARMACEUTICALS AND VIVET THERAPEUTICS ENTER INTO EXCLUSIVE WORLDWIDE OPTION AND LICENSE AGREEMENT FOR VIVET’S GENE THERAPY PROGRAMS TARGETING PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS.         – Mirum expands potential opportunities across rare disease pipeline – Vivet to lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2…

Vivet Therapeutics, participada por Ysios Capital y Columbus Venture, cierra una opción exclusiva de licencia con Mirum Pharmaceuticals

Inversión, Venture Capital

13/04/2021 Nota de prensa MIRUM PHARMACEUTICALS Y VIVET THERAPEUTICS FIRMAN UN ACUERDO EXCLUSIVO DE OPCIÓN Y LICENCIA A ESCALA MUNDIAL PARA LOS PROGRAMAS DE TERAPIA GÉNICA DE VIVET DIRIGIDOS A LA COLESTASIS INTRAHEPÁTICA FAMILIAR PROGRESIVA.         – Mirum amplía las oportunidades potenciales en la cartera de enfermedades raras – Vivet dirigirá el…